I recommend you check out Dr. Kamyar Kalantar-Zadeh's oral presentation from last year's ERA-EDTA symposium. Maybe not a layperson level, but a great summary of the effect of apabetalone on alkaline phosphatase, the association between alkaline phosphatase and vascular calcificaiton, and the connection between alkaline phosphate/vascular calcification and cardiovascular disease.

https://pace-cme.org/2018/08/20/a-clinical-view-on-bet-inhibition-in-ckd-cvd-understanding-recent-data-and-future-perspectives/

Additionally, stay tuned for the ERA-EDTA symposium on Saturday that will focus on BET inhibition and its effects on alkaline phosphatase and vascular calcification.

Here is the agenda for the symposium on Saturday June 15th (1:15 – 2:45 PM Hungary time) "Vascular calcification in kidney disease: Epigenetics as a novel approach?" The symposium presentations will be made available on the Company’s website HERE shortly after the live event.

Educational objectives:

• To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with CKD
• To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
• To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
• To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in prevention and management of CKD & CVD

Agenda:

• Introduction - Peter Stenvinkel, MD Stockholm, Sweden
• Epigenetic mechanisms targeting ALP: A pathway for prevention? - Marta Ruiz-Ortega, MD,Madrid, Spain
• The role of ALP as predictor of cardiovascular events and vascular calcification in CKD - Mathias Haarhaus, MD, Stockholm, Sweden
• Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition - Vincent M Brandenburg, MD, Aachen, Germany
• Panel discussion - Jurgen Floege, MD Aachen, Germany